Wed, 07th Sep 2022 09:55
ImmuPharma PLC - specialist drug discovery and development company - Says L1 Capital Global Opportunities Master Fund has exercised options over 3.0 million new shares at a price of 5 pence each, for GBP150,000 in total. The new shares represent 0.9% of the company's enlarged share capital.
Current stock price: 6.36 pence
12-month change: down 19%
By Sophie Rose; sophierose@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
(Alliance News) - Immupharma PLC on Tuesday announced a new intellectual property strategy to significantly enhance the patent life and commercial val...
(Alliance News) - ImmuPharma PLC on Monday noted updates on Incanthera PLC's commercial skincare deal with Marionnaud, which was first announced in De...
(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central b...
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.
(Alliance News) - The following is a round-up of earnings and trading updates of London-listed companies, issued on Wednesday and not separately repo...
Immupharma (IMM)